IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Company profile
Ticker
ISO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
IsoPlexis UK Limited • IsoPlexis (Shanghai) Trading Co., Ltd. ...
IRS number
462179799
ISO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
31 Mar 23
8-K
Entry into a Material Definitive Agreement
22 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
S-8 POS
Registration of securities for employees (post-effective amendment)
21 Mar 23
25-NSE
Exchange delisting
21 Mar 23
425
Business combination disclosure
16 Mar 23
425
Business combination disclosure
16 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
16 Mar 23
DEFA14A
Additional proxy soliciting materials
9 Mar 23
425
Business combination disclosure
9 Mar 23
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.47 mm | 37.47 mm | 37.47 mm | 37.47 mm | 37.47 mm | 37.47 mm |
Cash burn (monthly) | 5.22 mm | 7.43 mm | 10.60 mm | 8.44 mm | 9.33 k | 2.66 mm |
Cash used (since last report) | 108.60 mm | 154.45 mm | 220.42 mm | 175.47 mm | 194.14 k | 55.36 mm |
Cash remaining | -71.14 mm | -116.98 mm | -182.96 mm | -138.01 mm | 37.27 mm | -17.89 mm |
Runway (months of cash) | -13.6 | -15.8 | -17.3 | -16.4 | 3993.3 | -6.7 |
Institutional ownership, Q1 2024
30.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 12.02 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Spring Mountain Capital G.P. | 6.06 mm | $0.00 |
Connecticut Innovations | 2.73 mm | $0.00 |
DHR Danaher | 1.98 mm | $0.00 |
North Sound Trading | 1.24 mm | $0.00 |